Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity
Fig 6
Pharmacodynamics of antigen-specific IgG following IdeS treatment.
Human serum samples from the 0.24 mg/kg BW group (n = 4) were addressed for presence of specific IgG against a vaccine mixture of antigens (diphtheria, pertussis, tetanus, polio and Haemophilus influenzae type b). The results are given as percent remaining IgG on the y-axis compared to the start value for each subject. To be able to follow both early, rapid degradation as well as recovery of IgG, graph A shows data up to 48 hours after dosing (x-axis in hours) and graph B shows data until last visit (x-axis in days).